Monte Rosa Therapeutics Total Debt Growth & History (GLUE)

Monte Rosa Therapeutics's total debt was $39.2M for fiscal 2025.

View full Monte Rosa Therapeutics company overview

Monte Rosa Therapeutics annual total debt history

Monte Rosa Therapeutics annual total debt

Fiscal yearPeriod endedTotal debtChangeGrowth
20252025-12-31$39.2M−$3.5M−8.25%
20242024-12-31$42.7M−$3.3M−7.22%
20232023-12-31$46.0M−$962,000−2.05%
20222022-12-31$47.0M$47.0M
20212021-12-31$0

Monte Rosa Therapeutics total debt trends

Between the periods ended 2021-12-31 and 2025-12-31, Monte Rosa Therapeutics's total debt increased from $0 to $39.2M, a change of $39.2M. The latest reported quarter, Q2 2026, shows $38.0M.

About the metric

What total debt means

Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.

Calculation and source

SEC-reported and combined total debt

TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Monte Rosa Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about GLUE yet. Start the conversation.

Write the first post